Ironsides Asset Advisors’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Ironsides Asset Advisors’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,058	Closed	-$4K	–	92
2022 Q4	$4K	Sell	1,058 -7	-0.7%	-$31	﹤0.01%	89
2022 Q3	$5K	Hold	1,065	–	–	﹤0.01%	85
2022 Q2	$6K	Sell	1,065 -7	-0.7%	-$39	﹤0.01%	98
2022 Q1	$8K	Hold	1,072	–	–	﹤0.01%	101
2021 Q4	$14K	Sell	1,072 -28	-3%	-$463	﹤0.01%	91
2021 Q3	$25K	Sell	1,100 -66	-6%	-$1.96K	0.01%	95
2021 Q2	$51K	Sell	1,166 -243	-17%	-$13.5K	0.02%	100
2021 Q1	$102K	Hold	1,409	–	–	0.03%	92
2020 Q4	$61K	Buy	1,409 +150	+12%	+$6.72K	0.02%	82
2020 Q3	$52K	Buy	1,259 +84	+7%	+$4.34K	0.02%	74
2020 Q2	$70K	Hold	1,175	–	–	0.02%	78
2020 Q1	$88K	Buy	+1,175	New	+$135K	0.05%	66

Other funds holding ORTX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Kapitalo Investimentos Sao Paulo, Brazil $531M AUM 25.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Ironsides Asset Advisors's ORTX Position: Q1 2023 in Review

Ironsides Asset Advisors sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2023, closing a stake of 1,058 shares — an estimated $4K sold.

Ironsides Asset Advisors first reported a position in ORTX in Q1 2020 and held it in 12 quarters. The position peaked at $102K in Q1 2021. 35 funds tracked by Wall St. Rank hold ORTX as of Q1 2023.

Ironsides Asset Advisors reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2023 after selling out during the quarter.
Ironsides Asset Advisors sold 1,058 Orchard Therapeutics plc American Depositary Shares shares in Q1 2023, an estimated $4K.
Ironsides Asset Advisors first reported a position in Orchard Therapeutics plc American Depositary Shares in Q1 2020 and held it in 12 quarters.
Ironsides Asset Advisors's Orchard Therapeutics plc American Depositary Shares position peaked at $102K in Q1 2021.
35 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2023.

Based on Ironsides Asset Advisors's 13F filing for Q1 2023, filed 11 May 2023.